Neurology by Wasay, Mohammad
Pakistan Journal of
Neurological Sciences (PJNS)
Volume 1 | Issue 2 Article 7
9-2006
Neurology
Mohammad Wasay
Aga Khan University
Follow this and additional works at: https://ecommons.aku.edu/pjns
Part of the Neurology Commons
Recommended Citation
Wasay, Mohammad (2006) "Neurology," Pakistan Journal of Neurological Sciences (PJNS): Vol. 1 : Iss. 2 , Article 7.
Available at: https://ecommons.aku.edu/pjns/vol1/iss2/7
V O L .  1 ( 2 )   J U L - S E P  2 0 0 6P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S  110
L I T E R A T U R E  H I G H L I G H T S
NEUROLOGY
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni
G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.
Vrije Universiteit Medical Center, Amsterdam, The Netherlands. ch.polman@vumc.nl
Selected abstracts and commentary
N Engl J Med. 2006 Mar 2;354(9):899-910
B A C K G R O U N D : Natalizumab is the first alpha4 integrin
antagonist in a new class of selective adhesion-molecule
inhibitors. We report the results of a two-year phase 3 trial of
natalizumab in patients with relapsing multiple sclerosis.
METHODS: Of a total of 942 patients, 627 were randomly
assigned to receive natalizumab (at a dose of 300 mg) and
315 to receive placebo by intravenous infusion every four
weeks for more than two years. The primary end points were
the rate of clinical relapse at one year and the rate of
sustained progression of disability, as measured by the
Expanded Disability Status Scale, at two years. R E S U L T S :
Natalizumab reduced the risk of sustained progression of
disability by 42 percent over two years (hazard ratio, 0.58;
95 percent confidence interval, 0.43 to 0.77; P<0.001).
The cumulative probability of progression (on the basis of
Kaplan-Meier analysis) was 17 percent in the natalizumab
group and 29 percent in the placebo group. Natalizumab
reduced the rate of clinical relapse at one year by 68 percent
(P<0.001) and led to an 83 percent reduction in the
accumulation of new or enlarging hyperintense lesions, as
detected by T2-weighted magnetic resonance imaging (MRI),
over  two years (mean numbers of lesions, 1.9 with
natalizumab and 11.0 with placebo; P<0.001). There were
92 percent fewer lesions (as detected by gadolinium-
enhanced MRI) in the natalizumab group than in the placebo
group at both one and two years (P<0.001). The adverse
events  that were signi f icantly more frequent in  the
natalizumab group than in the placebo group were fatigue
(27 percent vs. 21 percent, P=0.048) and allergic reaction
(9 percent vs. 4 percent, P=0.012). Hypersensitivity
reactions of any kind occurred in 25 patients receiving
natalizumab (4 percent), and serious hypersensitivity
react ions occur red in 8 pat ients (1 percent).
C O N C L U S I O N S : Natalizumab reduced the risk of the
sustained progression of disability and the rate of clinical
relapse in patients with relapsing multiple sclerosis.
Adhesion-molecule inhibitors hold promise as an effective
treatment for relapsing multiple sclerosis.
(ClinicalTrials.gov number, NCT00027300.). 
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NATALIZUMAB FOR 
RELAPSING MULTIPLE SCLEROSIS
COMMENTARY
Natalizumab is an adhesion-molecule inhibitor. The study by Polman and colleagues is a randomized, placebo-controlled
trial to test the efficacy of this agent in relapsing multiple sclerosis. Decreased long term disability is reported in the drug-
treated group. These findings are promising and further studies are needed to extend their influence into clinical practice.
After many disappointing trials related to neuroprotective agents in ischemic stroke, an encouraging result has been
reported by the SAINT-I investigators. NXY-059 is a free-radical scavenger that showed marginal benefit in the treated
group. The findings are unlikely to impact clinical practice, although they are promising for ongoing research in this field and
are likely to trigger new studies. 
The study by Bhatt et al looks at a burning question in secondary stroke prevention, namely, whether addition of clopidogrel
to aspirin offers added benefit in reducing recurrent events. It is a large, well-conducted study looking at standard vascular
outcomes and end-points. As with the MATCH trial, the authors conclude that the combination offers no advantage over
aspirin alone.
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N Engl J Med. 2006 Feb 9;354(6):588-600
B A C K G R O U N D : NXY-059 is a free-radical-trapping agent
that is neuroprotective in animal models of stroke. We tested
whether it would reduce disability in humans after acute
ischemic stroke. M E T H O D S : We conducted a randomized,
double-blind, placebo-controlled trial involving 1722 patients
with acute ischemic stroke who were randomly assigned to
receive a 72-hour infusion of placebo or intravenous NXY-
059 within 6 hours after the onset of the stroke. The primary
outcome was disability at 90 days, as measured according to
scores on the modified Rankin scale for disability (range, 0 to
5, with 0 indicating no residual symptoms and 5 indicating
bedbound, requiring constant care). R E S U L T S : Among the
1699 subjects included in the efficacy analysis, NXY-059
significantly improved the overall distribution of scores on the
modified Rankin scale, as compared with placebo (P=0.038
by the Cochran-Mantel-Haenszel test). The common odds
ratio for improvement across all categories of the scale was
1.20 (95 percent confidence interval, 1.01 to 1.42).
Mortality and rates of serious and nonserious adverse events
were each similar in the two groups. NXY-059 did not
improve neurologic functioning as measured according to the
National Institutes of Health Stroke Scale (NIHSS): the
difference between the two groups in the change from
baseline scores was 0.1 point (95 percent confidence
interval, -1.4 to 1.1; P=0.86). Likewise, no improvement
was observed according to the Barthel index (P=0.14). In a
post hoc analysis of patients who also received alteplase,
NXY-059 was associated with a lower incidence of any
hemorrhagic transformation (P=0.001) and symptomatic
intracranial hemorrhage (P=0.036). C O N C L U S I O N S : T h e
administration of NXY-059 within six hours after the onset of
acute ischemic stroke significantly improved the primary
outcome (reduced disability at 90 days), but it did not
significantly improve other outcome measures, including
neurologic functioning as measured by the NIHSS score.
Additional research is needed to confirm whether NXY-059 is
beneficial in ischemic stroke. (ClinicalTrials.gov number,
NCT00119626.) 
NXY-059 FOR ACUTE ISCHEMIC STROKE
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD,
Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg
PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators
Cleveland Clinic, Cleveland, USA
N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.
B A C K G R O U N D : Dual antiplatelet therapy with clopidogrel
plus low-dose aspirin has not been studied in a broad
population of patients at high risk for atherothrombotic
events. METHODS: We randomly assigned 15,603 patients
with either clinically evident cardiovascular disease or
multiple risk factors to receive clopidogrel (75 mg per day)
plus low-dose aspirin (75 to 162 mg per day) or placebo
plus low-dose aspirin and followed them for a median of 28
months. The primary efficacy end point was a composite of
myocardial infarction, stroke, or death from cardiovascular
causes. RESULTS: The rate of the primary efficacy end point
was 6.8 percent with clopidogrel plus aspirin and 7.3
percent with placebo plus aspirin (relative risk, 0.93; 95
percent confidence interval, 0.83 to 1.05; P=0.22). The
respective rate of the principal secondary efficacy end point,
which included hospitalizations for ischemic events, was
16.7 percent and 17.9 percent (relative risk, 0.92; 95
percent confidence interval, 0.86 to 0.995; P=0.04), and
the rate of severe bleeding was 1.7 percent and 1.3 percent
(relative risk, 1.25; 95 percent confidence interval, 0.97 to
1.61 percent; P=0.09). The rate of the primary end point
among patients with multiple risk factors was 6.6 percent
CLOPIDOGREL AND ASPIRIN VERSUS ASPIRIN ALONE FOR THE PREVENTION OF
ATHEROTHROMBOTIC EVENTS
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with clopidogrel and 5.5 percent with placebo (relative risk,
1.2; 95 percent confidence interval, 0.91 to 1.59; P=0.20)
and the rate of death from cardiovascular causes also was
higher with clopidogrel (3.9 percent vs . 2.2 percent,
P=0.01).  In the subgroup with cl inical ly  ev ident
atherothrombosis, the rate was 6.9 percent with clopidogrel
and 7.9 percent with placebo (relative risk, 0.88; 95 percent
confidence interval , 0.77 to 0.998; P=0.046).
C O N C L U S I O N S : In this trial, there was a suggestion of
benef it wi th c lopidogrel t reatment in patients with
symptomatic atherothrombosis and a suggestion of harm in
patients with multiple risk factors. Overall, clopidogrel plus
aspirin was not significantly more effective than aspirin alone
in reducing the rate of myocardial infarction, stroke, or death
from cardiovascular causes. (ClinicalTrials.gov number,
NCT00050817.). 
